Miller School of Medicine, University of Miami, Miami, Florida, USA.
Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Oncologist. 2020 Jul;25(7):e1124-e1126. doi: 10.1634/theoncologist.2020-0101. Epub 2020 May 18.
Low-grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK-inhibitors displays synergism in preclinical ovarian cancer models, however. This brief communication presents the use of combination anti-estrogenic and MEK-inhibitor therapies, fulvestrant and trametinib, as treatment in a heavily pretreated patient with estrogen receptor-positive, recurrent LGSOC. The dual-therapy regimen was well tolerated and appeared to confer 9 months of progression-free survival. Further investigation is warranted to explore this effect.
低级别浆液性卵巢癌 (LGSOC) 已知具有化疗耐药性。复发性疾病的有效治疗选择很少，通常仅限于激素拮抗。然而，在内分泌治疗与 MEK 抑制剂联合使用的情况下，在临床前卵巢癌模型中显示出协同作用。本简要通讯介绍了在雌激素受体阳性、复发性 LGSOC 的重度预处理患者中使用联合抗雌激素和 MEK 抑制剂治疗，即氟维司群和曲美替尼。该双重治疗方案耐受性良好，似乎可提供 9 个月的无进展生存期。需要进一步研究来探索这种效果。
